title: ∆(9)-Tetrahydrocannabinol decreases NOP receptor density and mRNA levels in human SH-SY5Y cells.
abstract: Several studies demonstrated a cross-talk between the opioid and cannabinoid system. The NOP receptor and its endogenous ligand nociceptin/orphanin FQ represent an opioid-related functional entity that mediates some non-classical opioid effects. The relationship between cannabinoid and nociceptin/NOP system is yet poorly explored. In this study, we used the neuroblastoma SH-SY5Y cell line to investigate the effect of delta-9-tetrahydrocannabinol (∆(9)-THC) on nociceptin/NOP system. Results revealed that the exposure to ∆(9)-THC (100, 150, and 200 nM) for 24 h produces a dose-dependent NOP receptor B                         (max) down-regulation. Moreover, ∆(9)-THC caused a dose-dependent decrease in NOP mRNA levels. The selective cannabinoid receptor CB1 antagonist AM251 (1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide) reduces both effects, suggesting that ∆(9)-THC activation of CB1 receptor is involved in the observed effects. These data show evidence of a cross-talk between NOP and CB1 receptors, thus suggesting a possible interplay between cannabinoid and nociceptin/NOP system.
authors: Department of Pharmacology, University of Bologna, Via Irnerio 48, Bologna, 40126, Italy.
authors: Rosalia
authors: R
authors: Cannarsa
authors: Donatella
authors: D
authors: Carretta
authors: Francesca
authors: F
authors: Lattanzio
authors: Sanzio
authors: S
authors: Candeletti
authors: Patrizia
authors: P
authors: Romualdi
references: Neuropeptides. 2007 Aug;41(4):239-47
references: 17512052
references: Neurosci Lett. 1999 Sep 17;272(3):183-6
references: 10505611
references: Eur J Neurosci. 1997 Jan;9(1):194-7
references: 9042583
references: Curr Drug Targets. 2010 Apr;11(4):393-405
references: 20017730
references: Methods Find Exp Clin Pharmacol. 1999 Jun;21(5):345-52
references: 10420390
references: Science. 1995 Nov 3;270(5237):792-4
references: 7481766
references: Eur J Pharmacol. 1997 Apr 4;323(2-3):193-5
references: 9128838
references: Pharmacol Rev. 2002 Jun;54(2):161-202
references: 12037135
references: Trends Pharmacol Sci. 1997 Aug;18(8):293-300
references: 9277133
references: J Comp Neurol. 1998 Sep 14;399(1):139-51
references: 9725707
references: Behav Brain Res. 2009 Jan 30;197(1):119-24
references: 18773925
references: Eur J Pharmacol. 1999 Aug 13;378(3):237-48
references: 10493099
references: Tetrahedron Lett. 1967 Mar;12:1109-11
references: 6039537
references: Trends Neurosci. 1998 May;21(5):215-21
references: 9610886
references: Pharmacol Rev. 2005 Jun;57(2):279-88
references: 15914470
references: Life Sci. 2004 Jan 30;74(11):1317-24
references: 14706563
references: Peptides. 2000 Jul;21(7):961-7
references: 10998529
references: J Pharmacol Sci. 2008 Nov;108(3):308-19
references: 19008645
references: Eur J Pharmacol. 2003 Aug 8;474(2-3):233-9
references: 12921868
references: Nature. 1995 Oct 12;377(6549):532-5
references: 7566152
references: J Pharmacol Exp Ther. 2002 Jun;301(3):963-8
references: 12023525
references: Eur J Pharmacol. 2002 May 10;442(3):237-9
references: 12065077
references: Br J Pharmacol. 2008 Jan;153(2):199-215
references: 17828291
references: Curr Drug Targets. 2010 Apr;11(4):406-28
references: 20196742
references: Psychopharmacology (Berl). 2001 Feb;154(1):1-7
references: 11291998
references: Br J Pharmacol. 2003 Jun;139(4):775-86
references: 12813001
references: Neuroscience. 1996 Nov;75(2):333-7
references: 8930999
references: J Pharmacol Exp Ther. 2001 Apr;297(1):121-7
references: 11259535
references: J Neurophysiol. 1997 Dec;78(6):3351-8
references: 9405549
references: Br J Pharmacol. 1996 May;118(2):205-7
references: 8735615
references: J Pharmacol Exp Ther. 1999 May;289(2):859-67
references: 10215664
references: Neuron. 2000 May;26(2):515-22
references: 10839369
references: J Neurosci. 2001 Jul 15;21(14):5344-50
references: 11438610
references: J Immunol Methods. 1983 Dec 16;65(1-2):55-63
references: 6606682
references: Peptides. 2000 Jul;21(7):1071-80
references: 10998542
references: Neuropharmacology. 2006 Sep;51(4):773-81
references: 16806307
references: Clin Exp Pharmacol Physiol. 2002 Mar;29(3):223-8
references: 11906488
references: Neurochem Int. 2009 Jun;54(7):452-7
references: 19428788
references: Neuroscience. 1996 Nov;75(1):1-4
references: 8923516
references: Pharmacol Biochem Behav. 2005 Jun;81(2):263-84
references: 15936806
references: Nature. 1998 Aug 6;394(6693):577-81
references: 9707118
references: Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14854-8
references: 9405703
references: Br J Pharmacol. 2006 Jun;148(4):387-95
references: 16682964
references: Br J Pharmacol. 2004 Jun;142(3):495-500
references: 15148260
references: Curr Drug Targets CNS Neurol Disord. 2005 Dec;4(6):643-55
references: 16375682
references: Neuroreport. 2004 Jun 7;15(8):1373-7
references: 15167569
references: Psychopharmacology (Berl). 2004 Mar;172(2):129-36
references: 14624329
references: Nat Rev Drug Discov. 2008 Aug;7(8):694-710
references: 18670432
references: Psychopharmacology (Berl). 1999 Jan;141(2):220-4
references: 9952048
references: Behav Pharmacol. 2002 May;13(3):229-35
references: 12122313
references: Life Sci. 1997;61(4):PL 39-43
references: 9244374
references: Neuroreport. 1996 Dec 20;8(1):369-71
references: 9051812
references: FEBS Lett. 1994 Mar 14;341(1):33-8
references: 8137918
references: Anal Biochem. 1987 Apr;162(1):156-9
references: 2440339